Nuvectis Pharma, Inc. (NVCT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1 Bridge Plaza
Fort Lee, NJ 07024
United States of America (the)
Phone
201 614 3150
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
February 04, 2022
| Name | Title | Pay | Year Born |
| Ron Bentsur | Co-Founder, Chairman, Chief Executive Officer & President | 1.19M | 1966 |
| Shay Shemesh | Co-Founder, Executive Vice President, Chief Development & Operations Officer | 749,241 | 1984 |
| Enrique Poradosu | Co-Founder, Executive Vice President, Chief Scientific & Business Officer | 749,241 | 1967 |
| Michael Carson | Vice President of Finance | 0 | 1976 |
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.